This week, the FDA granted priority review status to J&J’s JNJ application seeking approval of key pipeline candidate ...

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a ...

Bagsværd, Denmark Friday, January 10, 2025, 11:00 Hrs [IST] ...

Johnson & Johnson received Priority Review of nipocalimab in generalized myasthenia gravis. GSK’s B7-H3-targeted ...

Novo Nordisk stock gains 3% as analysts at UBS upgrade the company's rating from Neutral to Buy based on strong brand ...